Boston Biomedical Leadership and Directors
Boston Biomedical is wholly owned by Sumitomo Dainippon Pharma Co., Ltd., which is traded on the Tokyo Stock Exchange. Its Board of Directors can be found here.
Boston Biomedical’s Board of Directors includes executive leadership of Sumitomo Dainippon Pharma Co., Ltd., and an external board member, William J. Rutter, Ph.D.
Chief Executive Officer
Patricia S. Andrews has been the Chief Executive Officer of Boston Biomedical since April 2017 and serves on its board. Ms. Andrews joined the company in 2013 and was previously its Chief Operating Officer.
Prior to joining Boston Biomedical, Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a U.S.-based biopharmaceutical company, where she led the transition from a clinical-stage research and development organization to a successful commercial enterprise, with the launch of its first-for-the-company, first-in-class, first-in-disease orphan oncology product. She established the commercial organization and led all functions within sales and marketing. She was also responsible for business development and completed multiple significant product licensing deals for Incyte, including one of the largest licensing deals in biotech in 2009.
Prior to her experience at Incyte, Ms. Andrews spent 17 years at Pfizer Inc., culminating in her role as Vice President and General Manager of the U.S. Oncology Business Unit, at the time a $900 million portfolio of products in colorectal cancer, breast cancer, and renal cell carcinoma. Ms. Andrews is an Executive Officer of Sumitomo Dainippon Pharma Co., Ltd. and serves on the board of GlycoMimetics [Nasdaq: GLYC]. Ms. Andrews received her MBA from the University of Michigan and a BA from Brown University.
Executive Vice President,
Head of Research and Development,
Chief Medical Officer
Edgar Braendle, M.D., Ph.D was appointed as Executive Vice President, Head of R&D and Chief Medical Officer of Boston Biomedical in October 2017. In this role, he leads the company’s discovery research and clinical strategies.
Dr. Braendle has more than 15 years of industry experience leading clinical development and oncology diagnostics and treatments. Prior to joining Boston Biomedical, he served as President and CEO of ARUP Laboratories, a national clinical and anatomic pathology reference laboratory. Previously, he spent more than a decade at Novartis Pharmaceutical Corporation, culminating in his role as Senior Vice President and Global Head of Companion Diagnostics. In this role, Dr. Braendle led the company’s precision medicine approach, delivering all complementary and companion diagnostics for Novartis medicines, and driving exploratory biomarker development. In an earlier position as Vice President, Global Head of Oncology Biologics, he developed Novartis oncology biologics in early to late stages, successfully filing eight investigational new drug applications.
Dr. Braendle received a medical degree and training in hematological malignancies and solid tumor oncology at the University of Aachen in Germany.
Senior Vice President,
Chief Commercial Officer
Dee Mahoney was appointed as Senior Vice President and Chief Commercial Officer of Boston Biomedical in April 2017. Ms. Mahoney brings more than 29 years of commercial experience in the biopharmaceutical industry in roles ranging from field sales to executive leadership. She is leading the commercialization of the company’s cancer stemness inhibitors, CDK9 inhibitor, cancer vaccine compounds and other oncology assets in development for the North American market.
Prior to joining Boston Biomedical, Ms. Mahoney was Co-Founder and President of DMH BioPharm Advisors, a boutique management-consulting firm. In this role, Ms. Mahoney partnered with biopharmaceutical companies to maximize the effectiveness of commercial strategies and reduce the risk of regulatory noncompliance. Previously, she spent 20 years at Pfizer Inc., culminating in the role of Senior Vice President and General Manager of Pfizer’s U.S. Specialty Products Business Unit, where she was responsible for the commercial operations and a $2.5 billion portfolio of oncology, anti-infective, HIV, ophthalmology and endocrine care products. Throughout her career, Ms. Mahoney has successfully launched twelve products with multiple new indications of existing products, and led teams of over 900 colleagues.
Ms. Mahoney received a Bachelor of Science degree in microbiology and organic chemistry from Stephen F. Austin State University. She has also received several continuing education certifications, including a Comprehensive Leadership Certificate from Harvard Business School, a Finance and Accounting Certificate from The Wharton School at the University of Pennsylvania, and a Healthcare Compliance Certificate from Seton Hall Law School.
Senior Executive Officer,
Global Head of Oncology,
Sumitomo Dainippon Pharma Co., Ltd.
Since joining Sumitomo Dainippon Pharma in 2011, Kazuo Koshiya, Ph.D. has led the establishment of the global R&D and business organizations for oncology. In April 2017, Dr. Koshiya was appointed to the Global Head of Oncology for Sumitomo Dainippon Pharma Group, taking the lead in the company’s overall oncology business, one of its core therapeutics areas. Under his leadership, Sumitomo Dainippon Pharma (DSP Cancer Institute, Oncology Clinical Development Unit), Boston Biomedical, Inc. and Tolero Pharmaceuticals, Inc. (Headquarters: Lehi, UT, U.S., CEO: David J. Bearss) will collaborate on research and development with the goal of continuously creating innovative compounds and accelerating filings and approvals of compounds in the development pipeline in order for oncology products to contribute to company performance as early as possible. In January 2017, Sumitomo Dainippon Pharma acquired Tolero Pharmaceuticals, a U.S.-based biotechnology company specializing in research and development of therapeutic agents in the areas of oncology and hematological disorders. This acquisition expanded Sumitomo Dainippon Pharma’s oncology and hematology portfolios.
Dr. Koshiya serves on the board of Boston Biomedical, Inc. and is chairman of the board of Tolero Pharmaceuticals, Inc.
Prior to Sumitomo Dainippon Pharma, Dr. Koshiya worked for Astellas Pharma Inc. for more than 20 years in Japan, the U.S., and the Netherlands. His responsibilities at Astellas included drug discovery, clinical development, R&D management, and business strategy. From 2007 to 2011, he served as Vice President, Product and Portfolio Strategy at Astellas headquarters. One of his achievements during this period was developing and implementing Astellas’ market entry strategy for oncology. Before entering the pharmaceutical industry, Dr. Koshiya was Assistant Professor of Neurophysiology at Kanazawa University.
Dr. Koshiya earned his Ph.D. in neuropharmacology from Tokyo Institute of Technology and a degree in pharmaceutical medicine from the European Center of Pharmaceutical Medicine in Switzerland.
Board of Directors
Member, Boston Biomedical Board of Directors,
CEO and Founder,
Dr. Rutter is Chairman and Founder of Synergenics, LLC, which owns and controls a portfolio of biotechnology companies at various stages of development.
In his academic career, Dr. Rutter joined the University of California–San Francisco (UCSF) as head of the newly formed department of Biochemistry and Biophysics in 1968, and played a key role in developing UCSF into a major scientific institution. In research, he is particularly known for the discovery of the enzymes involved in the expression of DNA (RNA polymerases), the first cloning of the insulin gene, the cloning of hepatitis B virus (HBV), and formation of an HBV-like particle that provided the basis for a safe and protective vaccine.
With two colleagues, Dr. Rutter founded Chiron in 1981, a pioneering biotech firm that developed the first recombinant vaccine (against HBV) with Merck and a process for manufacturing insulin from yeast with Novo-Nordisk. Chiron was the first to clone the AIDS (HIV) virus and to discover, clone, and sequence the hepatitis C virus (HCV). Chiron developed quantitative diagnostic tests for HIV, HBV, and HCV, thus providing the means for eliminating blood contaminated with these viruses, a major contribution to public health worldwide. Chiron developed and promulgated the concept of “viral load” as the basis for determining disease status, as well as the basis for developing and evaluating antivirals and other treatment protocols for these and other diseases.
Prior to Chiron, Dr. Rutter was a consultant to Abbott Laboratories for about 20 years, and a member of the Amgen Scientific Advisory Board. Dr. Rutter’s past board memberships include Novartis, Sangamo Biosciences, Cytokinetics, Nugen, Oscient Pharmaceuticals, and Epitomics.
Dr. Rutter also currently serves on the boards of Eureka Genomics, Apexigen, One Globe, and Cellworks. He is Chairman of the Synergenics companies: Synco Biopartners, ReLIA Diagnostic Systems, Numera Health, Ventria Bioscience, Humabs Biomed, Pathologica, and BioEnergenix. Dr. Rutter is a member of the National Academy of Sciences and the American Academy of Arts and Sciences, and has received numerous awards for his contributions to science and the biotechnology industry.